- Trial phase
- Phase 1/2 (MAD - Multiple Ascending Dose)
- Time to market
- SRP-1003 is in early-stage clinical development (Phase 1/2 MAD study). If the upcoming data supports advancement, a Phase 3 program would follow, meaning regulatory approval and commercialization are likely several years away (estimated 2029-2031 at the earliest).
- Why 5/10
- The next hard catalyst is the multiple ascending dose (MAD) data readout for SRP-1003 in DM1, expected by year-end 2026 (Q4 2026). This is an early-stage (Phase 1/2) data readout, not a pivotal/registration readout or PDUFA date. Sarepta has substantial commercial revenue (~$1.25B-$1.3B in 2026 guidance) from its approved DMD franchise, so SRP-1003 is one of several pipeline assets rather than the sole value driver. ImpactScore is 5: a near-term binary catalyst on a meaningful pipeline asset at a company with other programs and commercial revenue.
The next catalyst is the multiple ascending dose (MAD) data readout for SRP-1003 in DM1, expected by year-end 2026 (Q4 2026, within ~2 months). Positive data could support advancement to Phase 3 and re-rate the stock; negative or equivocal data would likely be viewed as a pipeline setback. The data readout is the single most important near-term pipeline catalyst for Sarepta alongside the SRP-1001 (FSHD) readout.
Price Chart
Executive Summary
SRP-1003 is Sarepta Therapeutics' investigational RNA-targeted therapy for myotonic dystrophy type 1 (DM1), a rare genetic neuromuscular disease with no approved disease-modifying treatments. The drug is in early-stage clinical development, and the next major catalyst is the multiple ascending dose (MAD) data readout expected by year-end 2026 (Q4 2026, within approximately two months). Sarepta is a commercial-stage biotech with ~$1.25B-$1.3B in projected 2026 revenue from its approved Duchenne muscular dystrophy franchise, giving it financial stability to advance pipeline candidates. The stock (SRPT) trades at $17.82 with a ~$1.96B market cap and mixed analyst consensus (mean target $21.64). The MAD data readout is a meaningful near-term catalyst but represents an early-stage pipeline event, not a registration decision.
How It Works
SRP-1003 is an investigational RNA-targeted therapy for myotonic dystrophy type 1 (DM1), a rare genetic neuromuscular disorder. While the exact mechanism is not publicly detailed, Sarepta specializes in antisense oligonucleotides that modulate RNA processing to correct underlying genetic defects. DM1 is caused by a repeated DNA sequence that produces toxic RNA, and SRP-1003 is designed to target that toxic RNA to restore normal cellular function.
Trial Status
SRP-1003 is in an early-stage multiple ascending dose (MAD) study for DM1. The company expects to report MAD data by year-end 2026 (Q4 2026). The data will inform whether the program advances to Phase 3 development.
The Two-Sided Case
Upcoming Catalysts
- MAD data readout for SRP-1003 (DM1) expected Q4 2026 (by year-end, within ~2 months)
- MAD data readout for SRP-1001 (FSHD) also expected Q4 2026
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Sarepta Therapeutics, Inc. 8-K SRPT ·Originating report